Print（PDF/58KB） Oct. 29, 2010 Finances

Revision of Financial Forecasts for the Fiscal Year Ending March 31, 2011

Dainippon Sumitomo Pharma Co., Ltd. announces revisions of its financial forecast for the year ending March 31, 2011, which reflects changes in the Company's business performances since the previous forecasts announced on July 30, 2010.

1. Revision of Consolidated Financial Forecasts for the Year Ending March 31, 2011

	Net sales	Operating income	Ordinary income	Net income	Earnings per share
Previous Forecasts (A)	359,000	8,500	6,000	3,000	¥7.55
New forecast (B)	365,000	18,000	15,500	9,000	¥22.65
(B)－(A)	6,000	9,500	9,500	6,000
Change (%)	1.7	111.8	158.3	200.0
(Reference) Results for the year ended March 31, 2010	296,261	35,624	33,837	20,958	¥52.75

2. Reason for revision
Sales are expected to exceed those of the previous forecasts because they are showing basically favorable trends both in Japan and overseas even though there are influences by yen's appreciation. Continued efforts are exerted for effective control of expense budget, and in addition, partly due to strong yen, some retrenchment is expected on the expenses of the Company's U.S. subsidiary, all contributing to possible reduction in the total expenses from the previous forecasts.
Consequently, in the revised consolidated financial forecasts for the year ending March31, 2011, the Company anticipates that net sales increase 6.0 billion yen to 365.0 billion yen, operating income increases 9.5 billion yen to 18.0 billion yen, ordinary income increases 9.5 billion yen to 15.5 billion yen and net income increases 6.0 billion yen to 9.0 billion yen compared to the previous forecasts dated July 30, 2010.

Note:Forecasts shown above are based on management's assumptions and beliefs in light of the information currently available, and involves risks and uncertainties.
Actual financial results may differ materially depending on a number of factors, including economic conditions.